These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 14644024)

  • 1. Vasopressin receptor antagonists in heart failure.
    Thibonnier M
    Curr Opin Pharmacol; 2003 Dec; 3(6):683-7. PubMed ID: 14644024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment options for hyponatremia in heart failure.
    Goldsmith SR
    Heart Fail Rev; 2009 Jun; 14(2):65-73. PubMed ID: 18777208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AVP receptor antagonists in patients with CHF.
    Kumar SK; Mather PJ
    Heart Fail Rev; 2009 Jun; 14(2):83-6. PubMed ID: 18766439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology of vasopressin antagonists.
    Costello-Boerrigter LC; Boerrigter G; Burnett JC
    Heart Fail Rev; 2009 Jun; 14(2):75-82. PubMed ID: 18766438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasopressin-receptor antagonists in heart failure.
    Schweiger TA; Zdanowicz MM
    Am J Health Syst Pharm; 2008 May; 65(9):807-17. PubMed ID: 18436727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of vasopressin antagonists in the management of acute decompensated heart failure.
    Orlandi C; Zimmer CA; Gheorghiade M
    Curr Heart Fail Rep; 2005 Sep; 2(3):131-9. PubMed ID: 16138949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AVP receptor antagonists as aquaretics: review and assessment of clinical data.
    Verbalis JG
    Cleve Clin J Med; 2006 Sep; 73 Suppl 3():S24-33. PubMed ID: 16970150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasopressin and vasopressin antagonists in heart failure and hyponatremia.
    Farmakis D; Filippatos G; Kremastinos DT; Gheorghiade M
    Curr Heart Fail Rep; 2008 Jun; 5(2):91-6. PubMed ID: 18765079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of vasopressin receptor antagonists.
    Ali F; Guglin M; Vaitkevicius P; Ghali JK
    Drugs; 2007; 67(6):847-58. PubMed ID: 17428103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of vasopressin-receptor antagonists in heart failure.
    Izumi Y; Miura K; Iwao H
    J Pharmacol Sci; 2014; 124(1):1-6. PubMed ID: 24401675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasopressin receptor antagonists in heart failure.
    Hobbs RE; Tang WH
    Recent Pat Cardiovasc Drug Discov; 2006 Jun; 1(2):177-84. PubMed ID: 18232127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasopressin antagonists in heart failure.
    Golestaneh L; Talreja A; Le Jemtel TH
    Curr Heart Fail Rep; 2004 Dec; 1(4):190-6. PubMed ID: 16036044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Vasopressin receptor antagonists and heart failure].
    Haass M
    Ther Umsch; 2009 Nov; 66(11):735-40. PubMed ID: 19885790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH).
    Gassanov N; Semmo N; Semmo M; Nia AM; Fuhr U; Er F
    Eur J Clin Pharmacol; 2011 Apr; 67(4):333-346. PubMed ID: 21327910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure.
    Rangasetty UC; Gheorghiade M; Uretsky BF; Orlandi C; Barbagelata A
    Expert Opin Investig Drugs; 2006 May; 15(5):533-40. PubMed ID: 16634691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasopressin antagonists: Pharmacotherapy for the treatment of heart failure.
    Reilly T; Schork MR
    Ann Pharmacother; 2010 Apr; 44(4):680-7. PubMed ID: 20332337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. V2 receptor antagonism with tolvaptan in heart failure.
    Costello-Boerrigter LC; Boerrigter G; Burnett JC
    Expert Opin Investig Drugs; 2007 Oct; 16(10):1639-47. PubMed ID: 17922627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasopressin and Vasopressin Antagonists in Heart Failure.
    Vishram-Nielsen JK; Gustafsson F
    Handb Exp Pharmacol; 2017; 243():307-328. PubMed ID: 28432473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
    Lanfear DE; Sabbah HN; Goldsmith SR; Greene SJ; Ambrosy AP; Fought AJ; Kwasny MJ; Swedberg K; Yancy CW; Konstam MA; Maggioni AP; Zannad F; Gheorghiade M;
    Circ Heart Fail; 2013 Jan; 6(1):47-52. PubMed ID: 23239836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Arginine vasopressin antagonism--new treatment option in chronic heart failure].
    Solberg OG; Omland T
    Tidsskr Nor Laegeforen; 2007 Jan; 127(2):179-82. PubMed ID: 17237865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.